10-Q: SANUWAVE Health Reports Q3 2026 Results, Faces Nasdaq Delisting Warning

SANUWAVE Health Inc. reported a 24% revenue decline for Q3 2026 and a net loss, while also addressing a Nasdaq delisting notice and a covenant breach on its credit facility.

Summary

• SANUWAVE Health reported a 24% decrease in revenue for the third quarter of 2026, totaling $8.6 million, compared to $11.3 million in the prior year period.
• For the nine months ended September 30, 2026, revenue decreased by 9% to $27.9 million from $30.7 million in the same period of 2025.
• The company incurred a net loss of $1.4 million for the third quarter of 2026, a significant shift from a net income of $9.7 million in the prior year.
• For the nine months ended September 30, 2026, the net loss was $3.5 million, compared to a net income of $4.1 million in the prior year.
• The company received a notice from Nasdaq on September 23, 2026, indicating its Market Value of Listed Securities (MVLS) was below the required $50 million minimum, with a compliance deadline of March 22, 2027.
• SANUWAVE Health was also not in compliance with the fixed charge coverage ratio covenant under its JPM Credit Agreement as of September 30, 2026, though a waiver was obtained on October 28, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to declining revenues, increased operating expenses, a net loss, and continued concerns regarding Nasdaq listing compliance and debt covenant adherence.

Positives

• Ultramist applicator revenue increased by approximately 2% to $6.9 million in Q3 2026 from $6.8 million in Q3 2025, driven by a 15% increase in unit volume.
• For the nine months ended September 30, 2026, Ultramist applicator revenue grew by approximately 10% to $20.9 million from $19.0 million in the prior year, due to a 21% increase in unit volume.
• Interest expense decreased significantly, by $1.5 million in Q3 2026 and $4.3 million for the nine months ended September 30, 2026, due to debt restructuring.
• The company obtained a waiver for its fixed charge coverage ratio covenant breach and believes it will be in compliance with covenants over the next twelve months.
• Stock-based compensation expense, while significant, is a non-cash charge that contributes to the company's overall financial picture.

Negatives

• Revenue for Q3 2026 decreased by 24% to $8.6 million from $11.3 million in Q3 2025, primarily due to a 73% decline in Ultramist system revenue.
• Revenue for the nine months ended September 30, 2026, decreased by 9% to $27.9 million from $30.7 million in the prior year, driven by a 43% decline in Ultramist system revenue.
• The company reported a net loss of $1.4 million for Q3 2026, compared to a net income of $9.7 million in Q3 2025.
• For the nine months ended September 30, 2026, the net loss was $3.5 million, compared to a net income of $4.1 million in the prior year.
• Operating expenses increased by 6% for the nine months ended September 30, 2026, to $15.3 million from $14.4 million in the prior year, driven by higher personnel, bad debt, audit, and software expenses.
• The company received a Nasdaq delisting warning due to low Market Value of Listed Securities (MVLS) and has until March 22, 2027, to regain compliance.
• SANUWAVE Health was not in compliance with a financial covenant (fixed charge coverage ratio) under its JPM Credit Agreement as of September 30, 2026.
• The company has an accumulated deficit of $246.2 million as of September 30, 2026.

Risks

• Changes in Medicare reimbursement for wound care products, including a significant reduction in payment for skin substitutes and a 21% reduction for CPT code 97610 (Ultramist treatment) in 2027, could reduce demand for systems and applicators and pressure pricing.
• The company did not comply with a financial covenant under its JPM Credit Agreement as of September 30, 2026, and future failures could lead to an event of default and acceleration of debt.
• The company received a notice from Nasdaq regarding its Market Value of Listed Securities (MVLS) being below the minimum requirement, risking delisting if compliance is not regained by March 22, 2027.
• The loss of single suppliers for product component materials or finished product assembly could disrupt production.
• The increased availability of used Ultramist systems in the market is impacting new system sales.
• Continued pressure on provider economics could alter treatment protocols, limit capital expenditures, and reduce demand for SANUWAVE's products.
• The company has identified material weaknesses in its internal control over financial reporting, primarily related to insufficient accounting resources and technical expertise.

Future Outlook

The company believes its current cash position, anticipated cash flows from operations, and availability under its revolving credit facility will be sufficient to meet its working capital needs, capital expenditures, and debt service obligations for at least the next twelve months. However, management acknowledges that compliance with debt covenants depends on achieving forecasted operating results and cash flows, which are subject to uncertainties.

Management Comments

• Management believes it is probable that the Company will be in compliance with the covenants under the JPM Credit Agreement at each measurement date over the next twelve months.
• Management intends to monitor its MVLS and consider available options to regain compliance with the applicable Nasdaq Listing Rules.
• Management believes the Company will have sufficient resources to meet its working capital needs, capital expenditures, and debt service obligations for at least the next twelve months.

Industry Context

StockSavvy.ai notes that the wound care market is highly sensitive to reimbursement policies. Recent changes by CMS, particularly the significant reduction in Medicare payments for skin substitutes and the upcoming decrease for CPT code 97610, directly impact customer economics and could dampen demand for SANUWAVE's products, a trend observed in the current quarter's results.

Comparison to Industry Standards

• The filing does not provide direct comparisons to specific industry benchmarks or competitors' financial results.
• The company mentions using EBITDA and Adjusted EBITDA to assess operational performance and benchmark against competitors, but these comparative figures are not detailed in this filing.
• The decline in system revenue due to the availability of used systems is a known challenge in the medical device industry, particularly for capital equipment.

Legal Proceedings

• The company is involved in various legal proceedings in the ordinary course of business, but does not believe any pending proceedings will have a material adverse effect on its business, consolidated financial position, results of operations, or cash flows.

Stakeholder Impact

• Shareholders: Potential delisting from Nasdaq, continued net losses, and uncertainty regarding future financial performance could negatively impact share price and investor confidence.
• Creditors: The company's covenant breach and subsequent waiver highlight potential risks to lenders, although management expects future compliance.
• Customers: Reduced Medicare reimbursement rates for wound care treatments could impact customer financial health, potentially leading to deferred or reduced capital purchases and affecting demand for SANUWAVE's products.
• Employees: Material weaknesses in internal controls and financial performance concerns may create an uncertain work environment.

Next Steps

• Regain compliance with Nasdaq's minimum MVLS requirement by March 22, 2027.
• Monitor MVLS and consider available options to regain compliance with Nasdaq listing rules.
• Continue to evaluate opportunities to enhance the capital structure and support the growth strategy.
• Finalize the remediation process for sales tax obligations upon receiving responses from remaining jurisdictions.
• Continue to implement measures to address material weaknesses in internal control over financial reporting.

Key Dates

Recommendation

The company faces significant headwinds including declining revenues, persistent net losses, a Nasdaq delisting warning, and a history of covenant breaches. While there are efforts to improve operations and financial controls, the immediate risks associated with listing compliance and the negative impact of reimbursement changes on customer demand outweigh the potential for near-term recovery. The lack of clear catalysts for significant improvement in the short to medium term suggests a sell recommendation.

Keywords

SANUWAVE Health, Ultramist, wound care, regenerative medicine, medical devices, revenue decline, net loss, Nasdaq compliance